版本:
中国

BRIEF-Genentech announces positive interim results for Emicizumab in phase III study of children with Hemophilia A

April 17 (Reuters) -

* Genentech announces positive interim results for Emicizumab in phase III study of children with Hemophilia A

* Genentech - results build upon data for Emicizumab in adults and adolescents with Hemophilia A and inhibitors to factor VIII

* Genentech - Emicizumab Prophylaxis reduced number of bleeds in children with Hemophilia A and inhibitors to factor VIII

Source text for Eikon:

company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐